IMARA, INC.

Company

Enliven Therapeutics, Inc.

Filed

October 24, 2022

Accession Number

0001104659-22-110941

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →